At a November 18 House Veterans’ Affairs subcommittee hearing, lawmakers pressed the Department of Veterans Affairs on four practical tests of its psychedelic-treatment rollout: which facilities will deliver treatment, how many trained clinicians they will have, what resources will pay for it, and how veterans outside the initial locations will get care. VA’s written testimony gave no site-level numbers, and the oral answers Behavioral Wire recorded gave none either. It described preparation, not capacity.

No investigational psilocybin- or MDMA-assisted treatment is FDA-approved, and VA’s written testimony says it will proceed with clinical implementation only after all regulatory approvals are complete. As of November 19, the committee has not posted an official transcript. Oral exchanges below are paraphrased from Behavioral Wire’s record of the hearing and have not been checked against an official transcript or the committee’s video; where a speaker could not be confirmed, the article says “a VA witness.” Written testimony and statements for the record are quoted directly.

Which facilities will treat patients

VA’s written testimony says it has selected ten facilities to serve as early implementers, educators or sites-in-training, chosen after quantitative and qualitative analysis for their expertise, physical space and operational capacity. That is a list of roles, not a count of treatment sites. VA’s witnesses told members that not every site would treat patients; some are meant to train providers.

They said clinicians need more than coursework: they must sit in dosing sessions beside an experienced provider, at the initial sites. The ten facilities are therefore both the first treatment capacity and the start of the training pipeline.

VA has not publicly named the sites. A VA witness said naming them while FDA reviews applications could imply that VA knows something nonpublic about those reviews. Rep. Maggie Goodlander (D-N.H.) asked for the list, and a VA witness said VA would provide it to the committee.

How many clinicians

VA’s witnesses gave no staffing numbers. They said VA’s research protocols include dosing sessions that alone can last six to eight hours, on top of preparation and integration, and called the treatments burdensome on staff time. They said VA has analyzed that time and wants each initial site resourced so that general mental health access does not suffer.

Submitted statements point to the same constraint. The American Psychiatric Association’s statement for the record says treatment may require several hours of direct observation, multiple clinicians and dedicated space, and may reduce the number of patients a clinic can serve and divert staff from other services. No staffing ratio, session schedule or per-site throughput was given for any VA facility, so how many veterans ten facilities could treat cannot be estimated from the record. What the testimony does show is why capacity is likely to be set by clinician time, supervised training and site resources that VA has not quantified.

The workforce figures measure different things. Goodlander said VA has about 500 fewer psychologists and psychiatrists than at the start of last year. ProPublica’s March analysis of VA workforce data, comparing January 2026 with January 2025, found about that many fewer in the two groups combined; a VA spokesman disputed its framing. The American Psychological Association’s written testimony counts psychologists only: down more than 300 since November 2024. The figures cover different groups and periods and do not conflict. VA officials said VA is recruiting and has found efficiencies. Goodlander asked VA to commit to giving the committee a staffing plan for the ten sites within 30 days, covering how many clinicians, where they come from and what it costs.

Authority, funding and readiness

Gradison, a VA senior adviser, told a member that VA already has the statutory authority it needs. VA also said its fiscal 2027 budget request did not include specific funding for this work, but that it has the resources to deploy the drugs safely. Behavioral Wire did not review VA’s budget documents. Those are three separate claims: legal authority, budget capacity and operational readiness. In the record reviewed, the first appears as VA’s position, the second as an assertion without figures, and the third not at all.

Outside witnesses were not persuaded that research money suffices. Leith States, a former acting assistant secretary for health at HHS, urged Congress to fund preparation through VA’s clinical services budget rather than its research office. Marion Coe of Pinney Associates said Congress may need to ensure funds for sites, training, pharmacy and controlled-substance procedures.

Veterans outside the first sites

Rural and isolated veterans were addressed mainly in terms of what comes later. VA said it will weigh travel and may refer veterans to other facilities. Community providers will not come first: VA expects outside networks to take time to build and says its integrated project team has a workstream on referrals, guardrails and information flowing back to VA. A VA witness said that after esketamine’s 2019 approval, billing codes and coverage took a long time, leaving private providers with cash payments and no infrastructure for FDA’s safety program, which is why VA wants to move first.

Who may deliver the treatment

Witnesses split on qualifications. The psychologists’ association called for licensed mental health providers, trauma-informed training and on-site observation during dosing. The psychiatrists’ association said treatment for depression, PTSD and other psychiatric indications should be led by a psychiatrist. Coe said responses she synthesized for a congressional caucus split between licensed-only and competency-based teams, and that a risk evaluation and mitigation strategy (REMS), a safety program FDA can attach to an approved drug, could set enforceable minimums. States said referral to a community provider should not transfer accountability away from VA. VA said training is necessary but not sufficient, and that it has not decided whether psychedelics fall under the written-consent policy VA announced in September.

What 2.1 million and four digits do and do not mean

VA serves about 9 million enrolled veterans, of whom about 6.4 million use its care. About 2.1 million of those have been diagnosed with treatment-resistant depression, major depressive disorder or PTSD. Gradison gave that figure at the Psychedelic Healthcare Forum in New York on October 15, and in Behavioral Wire’s record he repeated it at the hearing. It counts VA patients with at least one of three diagnoses. It does not count veterans confirmed eligible for any psychedelic treatment, which depends on indications FDA has not approved, clinical screening and any REMS. A VA official said VA could not give a firm count of eligible veterans until it applies detailed criteria and sees any REMS.

The October 15 remarks also produced the warning Psychedelic Alpha reported on October 22, along with the ten-facility plan: “to manage expectations, it’ll be a challenge in the first year to treat four digits’ worth of patients.” It was a caution about the difficulty of first-year delivery, not an official VA capacity estimate or limit, and it should not be set against the 2.1 million as a measure of unmet eligibility.

Approval is not implementation

Gradison described the sequence: FDA approval of a new drug application, DEA rescheduling of compounds now in Schedule I, state processes, then commercial availability. He said three applications are pending at FDA and did not name them. The record shows different stages. Compass Pathways announced on November 9 that it had completed its submission for COMP360 psilocybin in treatment-resistant depression. Coe’s written testimony describes Usona’s psilocybin and Resilient’s MDMA applications as submitted; States’s statement cites press reports and a nonprofit’s statement for them, and Usona declined comment on the reported filing. The testimony does not say whether FDA has accepted any application for review.

Psilocybin and MDMA products therefore remain investigational. Esketamine, by contrast, has been FDA-approved since 2019 for treatment-resistant depression and carries a REMS. VA’s experience with it is the closest precedent for delivery, not evidence that the investigational drugs can be delivered at scale. An oversight hearing sets no policy, and enthusiasm for speed is not evidence of effectiveness.

The record shows what VA has established: ten selected sites, supervised experience before treating, and no clinical use before approval. It does not show how many of the ten will treat patients, with how many clinicians, funded how, or how a veteran far from one of them reaches care. Congress now has two open requests: the site list a VA witness said VA would provide, and the staffing plan Goodlander asked for, covering clinician numbers, sources and cost. Those documents, more than the October estimates, will show whether preparation is becoming access.